The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon


Work +617 570 1000
Fax +617 523 1231

Mitchell Bloom

Work +1 617 570 1055


Partner Chair, Life Sciences Practice


Mitchell Bloom is national Chair of Goodwin Procter’s Life Sciences Practice. Mr. Bloom specializes in representing public and private life science companies, as well as venture capital firms and investment banks focused on the life sciences sector, including matters involving biotechnology, medical devices, diagnostics and healthcare information technology.


J.D., 1989 Boston College Law School B.S., 1986 Suffolk University (cum laude)

United States: Finance

Capital markets: equity offerings

Within: Capital markets: equity offerings

Goodwin’s equity practice continues to go from strength to strength, particularly in the technology, telecoms and life sciences areas. Silicon Valley-based technology specialist Richard Kline led the group’s marquee deal of recent times, advising Atlassian on its headline IPO at the end of 2015. In another technology highlight, Anthony McCusker acted for Twilio in its $150m IPO. Among the firm’s life sciences work, Boston’s Mitchell Bloom advised BeiGene on its $158m IPO. Boston-based capital markets chair Ettore Santucci is also recommended and advised JP Morgan Securities, as underwriters, on Washington REIT’s $150m follow-on offering. In 2017, Silicon Valley-based Rezwan Pavri left for Wilson Sonsini Goodrich & Rosati.

[back to top]

United States: Industry focus

Healthcare: life sciences

Within: Healthcare: life sciences

Goodwin’s transactional practice had another prolific year advising Centerview Partners (acting as the investment bank) on a number of multibillion-dollar acquisitions, which included AbbVie’s acquisition of Pharmacyclics, Galenica Group’s buyout of Relypsa and Arbor Pharmaceuticals’ deal to buy XenoPort. It also assisted Galapagos on its $2bn global partnership with Gilead Sciences, for the development and commercialization of the JAK-1-selective inhibitor filgotinib, a potential treatment for rheumatoid arthritis. Among other impressive highlights, the team advised longstanding client Moderna Therapeutics on a $474m financing, and won an appeal for Teva Pharmaceuticals in a patent case involving generic forms of Lovenox (enoxaparin sodium). Boston-based Kingsley Taft and Mitchell Bloom are co-heads of the practice, which recruited Richard Hoffman and Scott Lassman from WilmerHale and Kleinfeld, Kaplan & Becker, LLP, respectively. The group also includes experienced Hatch-Waxman litigation specialists Daryl Wiesen and David Hashmall.

[back to top]

United States: M&A/corporate and commercial

Venture capital and emerging companies

Within: Venture capital and emerging companies

Goodwin has a team of over 180 lawyers dedicated to venture capital work, advising clients from the life science and technology industries on financing, investing and M&A matters and assisting start-ups originating from Silicon Valley, San Francisco, Boston, New York, Los Angeles and Washington DC. Boston-based John Egan, Bill Schnoor and Mitchell Bloom jointly head the technology and life sciences practice and Menlo Park-based Anthony McCusker leads the technology companies practice. Work highlights included advising cloud communications platform Twilio on its $150m IPO; advising fintech company Affirm on its $100m Series D financing, which was led by Founders Fed and included existing investors, such as Lightspeed Venture Partners and Spark Capital, as well as new investors; and handling Slack Technologies’ $200m Series F funding round, bringing its valuation to $3.8bn. New hires included William Growney and Michael Russell in Menlo Park - from an in-house position at Rich Relevance and Wilson Sonsini Goodrich & Rosati respectively - and Richard Hoffman in Boston from WilmerHale.

[back to top]

Back to index

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to